Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| UM1AI104681 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | NIH |
| Parexel | INDUSTRY |
| BioMérieux | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This study is a 2-arm, multicenter, multinational, prospective, randomized, controlled clinical trial. Hospitalized subjects with blood cultures growing Gram negative bacilli (GNB) will be randomized 1:1 to have the positive blood cultures characterized using standard of care (SOC) antimicrobial susceptibility testing (AST) vs. a rapid AST method known as Reveal™ in addition to SOC AST. The purpose of the FAST trial is to evaluate whether use of a rapid phenotypic AST improves clinical outcomes compared to use of SOC AST methods in clinical settings with high resistance rates.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard of Care | No Intervention | When a blood culture growing GNB is randomized standard of care arm the positive blood cultures will be characterized using standard of care antimicrobial susceptibility testing (AST) | |
| Reveal | Active Comparator | When a blood culture growing GNB is randomized to the Reveal arm, the positive blood culture will be characterized using Reveal, a rapid AST, and the standard of care AST. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Reveal | Diagnostic Test | Reveal is a rapid AST method, which uses small molecule sensor technology to detect growth of bacterial populations by measuring volatile metabolites, and provides AST results in ~5 hours. Reveal™ is approved for clinical use in the European Union (EU) and Israel and approval is in process in India, and provides minimum inhibitory concentrations (MICs) for 28 antibiotics and 9 Gram negative species, that together account for ~90% of organisms causing Gram negative blood stream infections (BSI). |
| Measure | Description | Time Frame |
|---|---|---|
| Subject Clinical Outcomes, as measured by Desirability of Outcome Ranking (DOOR) | The composite 3-category DOOR outcome will assess three deleterious events (unsuccessful discharge, lack of clinical response, and undesirable events) in addition to survival up to 30 days after Gram stain result. The primary DOOR outcome measure is defined using three ordered levels. From best to worst, they are:
| Up to 30 days after Gram stain result |
| Measure | Description | Time Frame |
|---|---|---|
| All-Cause Mortality | All-cause in-hospital mortality up to 30 days post Gram stain result | Up to 30 days post Gram Stain |
| Hospital Stay Length | Length of index stay in the hospital up to 30 days post Gram stain result, for those subjects alive at 30 days. Length of stay will be calculated as date of discharge minus date of Gram stain result. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ritu Banerjee, MD, PhD | Vanderbilt University Medical Center | Principal Investigator |
| Vance Fowler, MD | Duke Clinical Research Institute | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Attikon University General Hospital | Chaïdári | Attica | 12462 | Greece | ||
| Tzaneio General Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41999287 | Derived | Banerjee R, Komarow L, Li Y, Mau D, Dodd A, Geres H, Greenwood-Quaintance K, Adler A, Baliga S, Chowers M, Chrysos G, Zarkotou O, Paul M, Pournaras S, Regueiro DS, Evans S, Chambers H, Fowler VG Jr, Patel R; Antibacterial Resistance Leadership Group. Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia: The FAST Randomized Clinical Trial. JAMA. 2026 May 26;335(20):1762-1773. doi: 10.1001/jama.2026.5487. | |
| 41225518 | Derived |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | May 27, 2026 | |
| Reset | Jun 22, 2026 |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| ICF | No | No | Yes | Informed Consent Form | Jun 22, 2022 | Jul 1, 2025 | ICF_000.pdf |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| May 27, 2026 | Jun 22, 2026 | |||
| Jun 30, 2026 |
| ID | Term |
|---|---|
| D018805 | Sepsis |
| ID | Term |
|---|---|
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
Patient and care provider will not know which arm subject is randomized into until after the stewardship team has review the Reveal results and provided feedback on initial therapies prescribed.
|
| up to 30 days post Gram stain result |
| Number of ICU admissions | ICU admission up to 30 days post Gram stain result | up to 30 days post Gram stain result |
| Number of participants with new Acquisition of Multi-Drug Resistant Organism (MDRO) and/or C. difficile | New acquisition is defined as detection of MDRO/C. difficile in subjects who do not have preceding clinical or surveillance cultures with these organisms in the prior 3 months. MDRO will be identified on routine clinical or surveillance samples using local laboratory diagnostic procedures and include: Methicillin-resistant Staphylococcus aureus Vancomycin-resistant Enterococcus species 3rd generation cephalosporin-non-susceptible Enterobacterales Carbapenem-resistant Enterobacterales, as defined by the Center for Disease Control and Prevention: resistant to imipenem, meropenem, doripenem, or ertapenem OR documentation that the isolate produces a carbapenemase Pseudomonas aeruginosa resistant to carbapenems/multi-drug resistant (resistant to aminoglycosides, cephalosporins, fluoroquinolones, and carbapenems) Carbapenem-resistant Acinetobacter species Candida auris | up to 30 days post Gram stain result |
| Time to effective antibiotic therapy | Time to effective antibiotic therapy within 3 days from Gram stain result, defined as treatment with an antibiotic (or antibiotic class) to which the blood isolate is susceptible based on standard of care (SOC) AST. | within 3 days from Gram stain result |
| Time to antibiotic escalation | Time to antibiotic escalation of Gram negative coverage in those who have antibiotic escalation within 3 days from Gram stain result. Escalation: Changing to a broader spectrum antibiotic, addition of one or more antibiotics, or conversion of oral (PO) to intravenous (IV) route. | within 3 days from Gram stain result |
| Time to antibiotic de-escalation of Gram negative coverage | Time to antibiotic de-escalation of Gram negative coverage in those who have antibiotic de-escalation within 3 days from Gram stain result. De-escalation: Changing to a narrower spectrum antibiotic , cessation of one or more antibiotics, or changing from an IV to PO route of appropriate drug (i.e. IV to PO ciprofloxacin or levofloxacin). | within 3 days from Gram stain result |
| Piraeus |
| 18536 |
| Greece |
| Kasturba Medical College, Mangalore | Attāvara | Mangalore | 575001 | India |
| Rambam Health Care Campus | Haifa | 3109601 | Israel |
| Meir Medical Center | Kfar Saba | 4428162 | Israel |
| Tel Aviv Sourasky Medical Center | Tel Aviv | 64239 | Israel |
| Complexo Hospitalario Universitario A Coruña (CHUAC) Sergas | A Coruña | 15006 | Spain |
| Banerjee R, Komarow L, Li Y, Wu Q, Sanchez-Gonzalez L, Mau D, Abbenante E, Schwager N, Dodd A, Souli M, Geres HS, Doernberg S, Greenwood-Quaintance K, Evans SR, Chambers HF, Fowler VG Jr, Patel R; Antibacterial Resistance Leadership Group. Study protocol for a multicenter, multinational prospective randomized controlled trial comparing outcomes in subjects with Gram-negative bacteremia who have blood culture evaluation using Fast Antibiotic Susceptibility Testing vs. standard of care testing: the FAST trial. Trials. 2025 Nov 12;26(1):500. doi: 10.1186/s13063-025-09228-4. |
| D013568 |
| Pathological Conditions, Signs and Symptoms |